Valneva (NASDAQ:VALN) Sees Strong Trading Volume – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN) shares saw strong trading volume on Monday . 16,361 shares traded hands during mid-day trading, a decline of 18% from the previous session’s volume of 19,952 shares.The stock last traded at $8.8150 and had previously closed at $8.95.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VALN. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Valneva in a research note on Monday, August 25th. Wall Street Zen downgraded Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Guggenheim reduced their target price on Valneva from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Valneva in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group set a $14.00 price objective on shares of Valneva and gave the stock a “buy” rating in a research note on Monday, August 25th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Valneva Stock Performance

The stock has a market cap of $749.32 million, a price-to-earnings ratio of -6.05 and a beta of 1.83. The company has a quick ratio of 1.36, a current ratio of 1.78 and a debt-to-equity ratio of 0.72. The company has a 50 day simple moving average of $9.37 and a 200 day simple moving average of $8.47.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Thursday, November 20th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.31). Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. The firm had revenue of $34.01 million during the quarter, compared to the consensus estimate of $48.85 million. As a group, equities research analysts forecast that Valneva SE Sponsored ADR will post 0.13 EPS for the current year.

Institutional Trading of Valneva

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. VSM Wealth Advisory LLC grew its stake in Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Valneva during the 3rd quarter worth approximately $124,000. Marex Group plc acquired a new stake in shares of Valneva during the 2nd quarter worth approximately $64,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Valneva during the 2nd quarter worth approximately $8,240,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.